Hitachi of Tokyo has received US Patent No. 7,445,755, “Method and apparatus for manufacturing beads array chip.” The patent describes a process of manufacturing a two-dimensional bead array on a chip by disposing a plurality of beads immobilized with a biomolecular probe in a bead array container in a predetermined order. Specifically, a container with first channels disposed in parallel with each other and a second channel crossing those channels is provided. A capillary is moved through the second channel of the container vertically. The capillary is moved downward to draw in and retain one bead stored in a bead-storing plate and then moved upward to the position of a desired first channel. In this state, pure water is fed to the first passage from a water-feed system and a water stream is generated by drawing the pure water in by a suction pump. The bead retained in the end of the capillary is then transferred by the water stream and finally blocked by a dam disposed in the first channel, where the bead is retained.
Microchips of Bedford, Mass., has received US Patent No. 7,445,766, “Medical device and method for diagnostic sensing.” The patent claims devices for use in medical diagnostics that include: a) a substrate; and b) a plurality of discrete reservoirs located in the substrate, each reservoir having at least one opening; c) at least one diagnostic substance contained in each reservoir; and d) at least one non-degradable barrier layer covering each reservoir opening. According to the patent, the barrier layer is permeable to an agent to be detected, where the diagnostic substance remains inside the reservoirs and can react with the agent to be detected.
Ocimum Biosolutions of Indianapolis has received US Patent No. 7,447,594, “Molecular cardiotoxicology modeling.” The patent claims a method for determining whether a test compound is a cardiotoxin by: a) exposing heart tissue or heart cells to the test compound; b) preparing a normalized gene-expression profile of at least ten genes for the heart tissue or heart cells, where the gene-expression profile contains the differential gene-expression values for those genes upon exposure to the test compound; c) comparing the gene-expression profile to a cardiotoxicity model; and d) scoring the comparison to determine whether the test compound is a cardiotoxin. According to the patent, the gene-expression profile is generated by hybridization of nucleic acids to a microarray, and is normalized for hybridization conditions, label intensity, and reading efficiency prior to comparison.